FDA Suspends Marketing and Sales of Iclusig Pending Investigation

In a bit of breaking news last night, the FDA has asked Ariad Pharmaceuticals to suspend marketing and sales of its chemotherapy drug Iclusig (ponatinib) until further notice.

Iclusig is used to treat chronic myeloid leukemia.

On Oct. 11, the FDA asked that Ariad halt all clinical trials of the drug due to blood clots.

Last night, the agency went a big step further.

Agency calls for discontinued use

First the agency said that any patients currently receiving Iclusig but not responding should discontinue it immediately.

Any patients who are responding to it and whose physicians believe that the benefits outweigh the risks need to be treated under a single-patient Investigational New Drug (IND) application, or under an expanded access registry program, for the time being.

Finally, unless there are simply no options left, healthcare professionals should not start anyone on the drug for the time being.

Severe side effects

According to the FDA, about one-quarter of patients in a phase II trial of the drug – and almost half of those in a phase I trial – experienced adverse side effects. The FDA stated:

[These patients] have experienced serious adverse vascular events, including fatal and life-threatening heart attack, stroke, loss of blood flow to the extremities resulting in tissue death, and severe narrowing of blood vessels in the extremities, heart, and brain requiring urgent surgical procedures to restore blood flow.

The FDA has launched an investigation, and until it reaches a conclusion, Iclusig has been ground to a halt.

Source: FDA

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap